Modelling the effect of a dengue vaccine on reducing the evolution of resistance against antibiotic due to misuse in dengue cases
Tóm tắt
This paper intends to check whether and how a hypothetical dengue vaccine could contribute to issue of evolution of bacteria resistance against antibiotics by reducing the number of patients that would inappropriately being treated with antibiotics. We use a new mathematical model that combines, in a novel way, two previously published papers, one on the evolution of resistance against antibiotics and one classical Ross-Macdonald model for dengue transmission. The model is simulated numerically and reproduces a real case of evolution of resistance against antibiotics. In addition the model shows that the use of a hypothetical dengue vaccine could help to curb the evolution of resistance against an antibiotic inappropriately used in dengue patients. Both the increase in the proportion of resistant bacteria due to the misuse of antibiotics in dengue cases as a function of the fraction of treated patients and the reduction of that proportion as a function of vaccination coverage occur in a highly non-linear fashion. The use of a dengue vaccine is helpful in reducing the rate of evolution of antibiotic resistance in a scenario of misuse of the antibiotics in dengue patients.
Tài liệu tham khảo
Medical milestones https://www.bmj.com/content/suppl/2007/01/18/334.suppl_1.DC2/milestones.pdf Accessed 1 Oct 2019.
Frost I, Van Boeckel TP, Pires J, Craig J, Laxminarayan R. Global Geographic Trends in AntimicrobialResistance: The Role of International Travel. J Travel Med. 2019. doi: https://doi.org/10.1093/jtm/taz036.
Scott JG, Cohen D, DiCicco-Bloom B, Orzano AJ, Jaen CR, Crabtree BF. Antibiotic use in acute respiratory infections and the ways patients pressure physicians for a prescription. J Fam Pract. 2001;50(10):853–8.
Nyquist AC, Gonzales R, Steiner JF, Sande MA. Antibiotic prescribing for children with colds, upper respiratory tract infections, and bronchitis. JAMA. 1998;279(11):875–7.
Laxminarayan R, et al. Access to effective antimicrobials: a worldwide challenge. Lancet. 2016;387:168–75.
Laxminarayan R, et al. Antibiotic resistance: the need for global solutions. Lance Infect Dist. 2013;13:1057–98.
Lim C, et al. Epidemiology and burden of multidrug-resistant bacterial infection in a developing country. Elife. 2016;5:e18082.
Malhotra-Kumar S, Lammens C, Coenen S, Van Herk K, Goossens H. Effect of azithromycin and clarithromycin therapy on pharyngeal carriage of macrolide resistant streptococci n healthy volunteers: a randomised, double-blind, placebo controlled study. Lancet. 2007;369:482–90.
Fridkin SK, et al. Intensive Care Antimicrobial Resistance Epidemiology (ICARE) Project and he National Nosocomial Infections Surveillance (NNIS) System Hospitals. The effect of vancomycin and third-generation cephalosporins on prevalence of vancomycin-resistant enterococci in 126 U.S. adult intensive care units. Ann Intern Med. 2011;135:183.
Daneman N, et al. Variability in antibiotic use across nursing homes and the risk of antibiotic-related adverse outcomes for individual residents. JAMA Intern Med. 2015;175:1331–99.
Costelloe C, Metcalf C, Lovering A, Mant D, Hay AD. Effect of antibiotic prescribing in primary care on antimicrobial resistance in individual patients. Systematic Review Meta-Analysis. BMJ. 2010;340:c2096.
Steinke D, Darvey P. Association between antibiotic resistance and community prescribing: a critical review of bias and confounding in published studies. Clin Infect Dis. 2011;33(suppl 3):S193–205.
Goossens H, Ferech M, Vander Stichele R, Elseviers M. ESAC-project group. Outpatients antibiotic use in Europe and association with resistance. A cross-national database study. Lancet. 2005;365:57–587.
Neu HC. The crisis in antibiotic resistance. Science. 1992;257:1064–73.
United Nations. Draft political declaration of the high-level meeting of the General Assembly on antimicrobial resistance. Available at http://www.un.org/pga/71/wp-content/upload/sites/40/2016/09/DGACM_GEEAD_ESCAB_AMR-Draft-Political-Declaration-1616108E.pdf. Accessed 27 Sept 2019.
World Health Organization. Global action plan on antimicrobial resistance. Available at www.who.int/antimicrobial-resistance/publications/global-action-plan/en/ Accessed 27 Sept 2019.
World Health Organization. Integrated surveillance of antimicrobial resistance. Available at https://apps.who.int/iris/bitstream/handle/10665/91778/9789241506311_eng.pdf;jsessionid=7C1284F3A5AE74619D3951A9FCE15719?sequence=1.
Collineau L, et al. Guidance on the selection of appropriate indicators fro quantification of antimicrobial usage in humans and animals. Zoonoses Public Health. 2017;64:165–84.
World Heath Organization. Dengue: guidelines for diagnosis, treatment, prevention and control. Geneva: World Health Organization; 2009. p. 1–147.
Wilder-Smith A, Ooi EE, Horstick O, Wills B. Dengue. Lancet. 2019;393(10169):350–63. https://doi.org/10.1016/S0140-6736(18)32560-1.
Murray NE, Quam MB, Wilder-Smith A. Epidemiolgy of dengue: past, present and future prospects. Clin Epidemiol. 2013;5:299–309.
Sandopa D, Nethi SK, Sreeram SC, Vijay NKG, Biradavolu V, Kakimani JV. Prescribing antibiotics to pediatric dengue patients: increasing risk of bacterial resistance. Pediat Indonesiana. 2018;58:53–8.
Adrizain R, Setiabudi D, Chairulfatah A. The inappropriate use of antibiotics in hospitalized dengue virus-infected hildren with presumed concurrent bacterial infection in teaching and private hospitals in Bandung, Indonesia. PLoS Negl Trop Dis. 2019;13(6):e0007438.
Trunfio M, Savoldi A, Viganò O, d’Arminio Monforte A. Bacterial coinfections in dengue virus disease: what we know and what is still obscure about an emerging concern. Infection. 2017;45:1–10.
Massad E, Lundberg S, Yang HM. Modeling and simulating the evolution of resistance against antibiotics. Int J Biomed Comput. 1993;33:65–81.
Burattini MN, Chen M, Chow A, Coutinho FA, Goh KT, Lopez LF, Ma S, Massad E. Modelling the control strategies against dengue in Singapore. Epidemiol Infect. 2008;136(3):309–19.
Mainous AG 3rd, Hueston WJ. The cost of antibiotics in treating upper respiratory tract infections in a medicaid population. Arch Fam Med. 1998;7(1):45–9.